Standard BioTools signs agreement to sell Microfluidics business to ARCHIMED; closing remains pending
Summary
Standard BioTools signed a definitive agreement on 5 October 2026 to sell its Microfluidics business to ARCHIMED. Closing is expected in approximately 30 days but has not occurred.
Source Date
October 5, 2026
Source checked
October 6, 2026
Event Type
Definitive asset-sale agreement
Event Date
October 5, 2026
Geography
United States; global life-science research market
Commercial Regulatory Status
Definitive agreement signed; NOT CLOSED. Expected to close in approximately 30 days subject to customary closing conditions.
Related CFCM Topics
Company Watch; Single-Cell Technology; Market Structure; Standard BioTools
Category
Company
Primary source
Read the source →Facts supported by cited sources
Standard BioTools announced on 5 October 2026 that it entered a definitive agreement to sell its Microfluidics business to ARCHIMED. The company states that closing is expected in approximately 30 days, subject to customary closing conditions, and that the Microfluidics business remains part of Standard BioTools until closing.
CFCM explainer
Definitive agreement signed → closing conditions → transaction closes only if conditions are satisfied.
Source/credit: CFCM transaction-status schematic based on the Standard BioTools primary investor release. Alt text: signed agreement followed by pending closing conditions.
Claims Requiring Caution
The sale has not closed. Future growth or innovation under ARCHIMED is forward-looking company language. Transaction terms were not disclosed in the primary release.
Why It Matters
Standard BioTools is simultaneously reshaping its Microfluidics and Mass Cytometry businesses. The Microfluidics sale is not core clinical flow cytometry, but it is a material company-structure signal for the broader single-cell tools market.
An announcement is not proof of availability or authorisation. Interpret status within the stated jurisdiction and evidence boundary.
Editor and independence disclosure →